Study Details
Design, interventions, and primary outcomes
About This Study
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
Design
Interventions / Regimen
- Drug: VLS-01-203 BU — VLS-01 buccal transmucosal administration
- Drug: VLS-01-BU Placebo — Placebo buccal transmucosal administration
Primary Outcomes
- Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score (Baseline to Day 29)
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-30
Completion: 2026-08-30
Sex: ALL
Volunteers: false
Enrollment: 142 (ESTIMATED)
- Drug: VLS-01-203 BU — VLS-01 buccal transmucosal administration
- Drug: VLS-01-BU Placebo — Placebo buccal transmucosal administration